All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

Brought to you by

Scientific Education Support logo

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

TypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2019-10-31T09:53:54.000Z

ESH 2019 | How will the use of FLT3 inhibitors evolve in the future?

By Alexander Perl
Featured
Alexander Perl
Oct 31, 2019
Share:

Bookmark this article

The AML Global Portal were delighted to speak to Alexander Perl, University of Pennsylvania, Philadelphia, US, during the European School of Hematology (ESH) Translational Research Conference on AML. We asked Alexander Perl: How will the use of FLT3 inhibitors evolve in the future? He describes the clinical use of FLT3 inhibitors in the relapsed/refractory setting.

How will the use of FLT3 inhibitors evolve in the future?

More about...
AML-related mutationsCrenolanibESH 2019FLT3-ITDFLT3-TKDGilteritinibMidostaurinQuizartinib

Your opinion matters

HCPs, what is your preferred format for educational content on the AML Hub?
15 votes - 79 days left ...

Related articles

Add bookmark

Editorial theme | An introduction to the use of transplantation for the treatment of AML

This article will look at the different stem cell sources used for HSCT, the patients selected for an HSCT, and the current major issues in the pre- and...

Nov 11, 2019
Add bookmark

Editorial theme | An introduction to the use of transplantation for the treatment of AML

This article will look at the different stem cell sources used for HSCT, the patients selected for an HSCT, and...

Nov 11, 2019
Add bookmark

Prof. Agnieszka Wierzbowska | ASH 2017 | Take home messages for Poland from ASH 2017

59th ASH Annual Meeting and Exposition, 9 - 12 Dec 2017, Atlanta, GA Professor Agnieszka Wierzbowska Copernicus Memorial Hospital, Lodz, PL

Dec 21, 2017
Add bookmark

Prof. Agnieszka Wierzbowska | ASH 2017 | Take home messages for Poland from ASH 2017

59th ASH Annual Meeting and Exposition, 9 - 12 Dec 2017, Atlanta, GA Professor Agnieszka Wierzbowska Copernicus...

Dec 21, 2017

Newsletter

Subscribe to get the best content related to AML delivered to your inbox